Foghorn Therapeutics Inc. announced on March 25, 2025, that new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, will be presented as an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The data will focus on FHD-909 in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in SMARCA4 mutant cancers.
The company also plans to present poster presentations on the Phase 1 trial design for FHD-909, as well as preclinical data for its Selective CBP degrader program and Selective EP300 degrader program. These presentations are expected to highlight the robust anti-tumor activities and unmatched selectivity of Foghorn's pipeline programs.
Foghorn confirmed that enrollment and dose escalation are on track in the ongoing Phase 1 trial evaluating FHD-909 in SMARCA4 mutated cancers, with an initial focus on non-small cell lung cancer (NSCLC). The upcoming data presentations are anticipated to further strengthen the promise of Foghorn's differentiated therapeutic programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.